165 related articles for article (PubMed ID: 36290907)
1. Influence of Active Surveillance on Gleason Score Upgrade and Prognosis in Low- and Favorable Intermediate-Risk Prostate Cancer.
Hu X; Miao J; Huang J; Qian L; Zhang D; Wei H
Curr Oncol; 2022 Oct; 29(10):7964-7978. PubMed ID: 36290907
[TBL] [Abstract][Full Text] [Related]
2. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis.
Chandrasekar T; Bowler N; Schneider A; Goldberg H; Mark JR; Trabulsi EJ; Lallas CD; Gomella LG
Urology; 2021 Sep; 155():101-109. PubMed ID: 34186134
[TBL] [Abstract][Full Text] [Related]
4. Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
Hayman J; Phillips R; Chen D; Perin J; Narang AK; Trieu J; Radwan N; Greco S; Deville C; McNutt T; Song DY; DeWeese TL; Tran PT
Prostate; 2018 Jun; 78(8):623-630. PubMed ID: 29520847
[TBL] [Abstract][Full Text] [Related]
5. Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance.
Meissner VH; Woll M; Ankerst DP; Schiele S; Gschwend JE; Herkommer K
World J Urol; 2021 Oct; 39(10):3763-3770. PubMed ID: 33973043
[TBL] [Abstract][Full Text] [Related]
6. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients.
Boehle A; Zywietz D; Robrahn-Nitschke I; Lusch A; König IR
Urol Oncol; 2023 Nov; 41(11):454.e17-454.e24. PubMed ID: 37714724
[TBL] [Abstract][Full Text] [Related]
7. Does the Gleason Score 7 Upgrading Always Predict Worse Prognosis?
Zhou J; Yu M; Ding J; Qi J
Clin Genitourin Cancer; 2023 Dec; 21(6):e412-e421. PubMed ID: 37248147
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis.
Sayyid RK; Benton JZ; Reed WC; Woodruff P; Terris MK; Wallis CJD; Klaassen Z
World J Urol; 2023 Jan; 41(1):93-99. PubMed ID: 36472651
[TBL] [Abstract][Full Text] [Related]
9. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
[TBL] [Abstract][Full Text] [Related]
10. Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.
Bracci S; Osti MF; Agolli L; Bertaccini L; De Sanctis V; Valeriani M
Radiat Oncol; 2016 Jun; 11():78. PubMed ID: 27276878
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
12. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.
Zumsteg ZS; Zelefsky MJ; Woo KM; Spratt DE; Kollmeier MA; McBride S; Pei X; Sandler HM; Zhang Z
BJU Int; 2017 Nov; 120(5B):E87-E95. PubMed ID: 28464446
[TBL] [Abstract][Full Text] [Related]
13. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
14. Favorable Gleason 3 + 4 Prostate Cancer Shows Comparable Outcomes With Gleason 3 + 3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance.
Lee H; Lee IJ; Byun SS; Lee SE; Hong SK
Clin Genitourin Cancer; 2017 Dec; 15(6):e1117-e1122. PubMed ID: 28843377
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial.
Nabid A; Carrier N; Vigneault E; Van Nguyen T; Vavassis P; Brassard MA; Bahoric B; Archambault R; Vincent F; Bettahar R; Wilke D; Souhami L
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):732-740. PubMed ID: 33901566
[TBL] [Abstract][Full Text] [Related]
16. Analysis of risk factors for Gleason score upgrading after radical prostatectomy in a Chinese cohort.
Zhang B; Wu S; Zhang Y; Guo M; Liu R
Cancer Med; 2021 Nov; 10(21):7772-7780. PubMed ID: 34528767
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Gleason score upgrading in a large African-American population.
Vora A; Large T; Aronica J; Haynes S; Harbin A; Marchalik D; Nissim H; Lynch J; Bandi G; McGeagh K; Kowalczyk K; Ghasemian R; Venkatesan K; Verghese M; Hwang J
Int Urol Nephrol; 2013 Oct; 45(5):1257-62. PubMed ID: 23864415
[TBL] [Abstract][Full Text] [Related]
18. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
19. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
[TBL] [Abstract][Full Text] [Related]
20. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
